Literature DB >> 23205074

Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes.

Yoshiki Shigematsu1, Takeshi Hanagiri, Hironobu Shiota, Koji Kuroda, Tetsuro Baba, Yoshinobu Ichiki, Manabu Yasuda, Hidetaka Uramoto, Mitsuhiro Takenoyama, Kosei Yasumoto, Fumihiro Tanaka.   

Abstract

It is not easy to induce cytotoxic T lymphocytes (CTLs) against cancer in in vitro culture. Regulatory T cells (Tregs) are considered to play a pivotal role in tumor immune escape. In this study, we analyzed the distribution of Tregs among tumor-infiltrating lymphocytes (TILs), regional lymph node lymphocytes (RLNLs) and peripheral blood lymphocytes (PBLs) in patients with lung cancer, and analyzed the effect of Tregs on the induction of CTLs in vitro. A total of 84 patients with non-small cell lung cancer underwent surgery between January 2003 and December 2004. The TILs, RLNLs and PBLs from these patients were subjected to a comparison analysis. The proportion of CD4(+)CD25(+)Foxp3(+) cells in these lymphocytes was determined by flow cytometry. The effects of Tregs on the induction of CTLs was analyzed by the depletion of Tregs in mixed lymphocyte-tumor cell culture (MLTC). The average proportions of Tregs in the TILs, RLNLs and PBLs were 10.4±9.5, 4.4±2.4 and 2.8±2.1%, respectively. The proportion of Tregs in the RLNLs was significantly higher than that in the PBLs (P<0.001); furthermore, TILs contained a larger number of Tregs than RLNLs (P=0.034). These Tregs substantially suppressed the induction of CTLs against autologous tumor cells. The depletion of Tregs in the MLTC resulted in the successful induction of CTLs. Tregs were found at a higher frequency in the TILs and RLNLs than in the PBLs in lung cancer patients. Since Tregs inhibited the induction of CTLs, the depletion of Tregs may represent a new therapeutic strategy for lung cancer patients.

Entities:  

Year:  2012        PMID: 23205074      PMCID: PMC3506612          DOI: 10.3892/ol.2012.815

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  43 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma.

Authors:  Mitsuhiro Takenoyama; Jean-Françis Baurain; Manabu Yasuda; Tomoko So; Masakazu Sugaya; Takeshi Hanagiri; Kenji Sugio; Kosei Yasumoto; Thierry Boon; Pierre G Coulie
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

3.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

4.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

5.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

8.  Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

Authors:  M K Levings; R Sangregorio; M G Roncarolo
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors:  François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

10.  CTLA-4 ligation blocks CD28-dependent T cell activation.

Authors:  T L Walunas; C Y Bakker; J A Bluestone
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

View more
  11 in total

Review 1.  The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention.

Authors:  Joanna Domagala-Kulawik
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Ther Targets       Date:  2018-04-10       Impact factor: 6.902

3.  Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.

Authors:  Tatiana Akimova; Tianyi Zhang; Dmitri Negorev; Sunil Singhal; Jason Stadanlick; Abhishek Rao; Michael Annunziata; Matthew H Levine; Ulf H Beier; Joshua M Diamond; Jason D Christie; Steven M Albelda; Evgeniy B Eruslanov; Wayne W Hancock
Journal:  JCI Insight       Date:  2017-08-17

4.  Effect of TGF-β1 on blood CD4+CD25high regulatory T cell proliferation and Foxp3 expression during non-small cell lung cancer blood metastasis.

Authors:  Yi Hu; Weibo Qi; Li Sun; Hui Zhou; Biliu Zhou; Zhiping Yang
Journal:  Exp Ther Med       Date:  2018-06-13       Impact factor: 2.447

Review 5.  Mechanisms of immune response regulation in lung cancer.

Authors:  Joanna Domagala-Kulawik; Iwona Osinska; Grazyna Hoser
Journal:  Transl Lung Cancer Res       Date:  2014-02

6.  Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Authors:  Amaia Martinez-Usatorre; Ece Kadioglu; Gael Boivin; Chiara Cianciaruso; Alan Guichard; Bruno Torchia; Nadine Zangger; Sina Nassiri; Ioanna Keklikoglou; Martina Schmittnaegel; Carola H Ries; Etienne Meylan; Michele De Palma
Journal:  Sci Transl Med       Date:  2021-08-11       Impact factor: 17.956

Review 7.  Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

Authors:  Angel Qin; David G Coffey; Edus H Warren; Nithya Ramnath
Journal:  Cancer Med       Date:  2016-07-15       Impact factor: 4.452

8.  Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal Lymphadenectomy.

Authors:  Joanna Domagala-Kulawik; Iwona Kwiecien; Juliusz Pankowski; Monika Pasieka-Lis; Dominika Wolosz; Marcin Zielinski
Journal:  Biomed Res Int       Date:  2017-08-02       Impact factor: 3.411

9.  Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans.

Authors:  Iwona Kwiecien; Anna Stelmaszczyk-Emmel; Malgorzata Polubiec-Kownacka; Dariusz Dziedzic; Joanna Domagala-Kulawik
Journal:  Cancer Immunol Immunother       Date:  2016-11-19       Impact factor: 6.968

10.  LAP TGF-Beta Subset of CD4(+)CD25(+)CD127(-) Treg Cells is Increased and Overexpresses LAP TGF-Beta in Lung Adenocarcinoma Patients.

Authors:  Lorenzo Islas-Vazquez; Heriberto Prado-Garcia; Dolores Aguilar-Cazares; Manuel Meneses-Flores; Miriam Galicia-Velasco; Susana Romero-Garcia; Catalina Camacho-Mendoza; Jose Sullivan Lopez-Gonzalez
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.